恒瑞医药：收到HRS-6257片等多款药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for clinical trials of HRS-6257 tablets, aimed at treating acute and chronic pain, with no similar drugs approved in the domestic market [1] Group 1: Clinical Trial Approvals - The company’s subsidiary, Shanghai Heng Rui Medicine Co., Ltd., has been granted a clinical trial approval notice for HRS-6257 tablets [1] - The company and its subsidiaries have also received approval for clinical trials of SHR-4375 injection, Adalimumab injection, SHR-8068 injection, Bevacizumab injection, HRS-4642 injection, and SHR-9839 (sc) injection [1] - These clinical trials are set to commence in the near future [1]